The Food and Drug Administration (FDA) has issued a Refuse to File letter for accelerated approval of Roche's trastuzumab-DM1 (T-DM1) Biologics License Application, which was submitted in July 2010. Roche had requested accelerated approval for T-DM1 based on the results of a single-arm Phase II study. In that study one third of advanced HER2 positive breast cancer tumors shrank. The patients had received on average seven prior medications, including two HER2 targeted agents. HER2 is the abbreviation for "human epidermal growth factor receptor 2"... 
More...
More...